JIR
REGN icon

James Investment Research’s Regeneron Pharmaceuticals REGN Stock Holding History

James Investment Research’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80
Closed -$58K – 633
2022
Q4 		$58K Buy
+80
New +$59K 0.01% 344
2020
Q4 		– Sell
-8,343
Closed -$4.67M – 537
2020
Q3 		$4.67M Buy
+8,343
New +$5.06M 0.43% 69
2019
Q2 		– Sell
-1,665
Closed -$684K – 765
2019
Q1 		$684K Buy
+1,665
New +$686K 0.04% 335

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

James Investment Research's REGN Position: Q1 2023 in Review

James Investment Research sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 80 shares — an estimated $58K sold.

James Investment Research first reported a position in REGN in Q1 2019 and held it in 3 quarters. The position peaked at $4.67M in Q3 2020. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • James Investment Research reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • James Investment Research sold 80 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $58K.
  • James Investment Research first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • James Investment Research's Regeneron Pharmaceuticals position peaked at $4.67M in Q3 2020.
  • 1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on James Investment Research's 13F filing for Q1 2023, filed 26 Apr 2023.